02306nas a2200253   4500000000100000008004100001653003900042653002500081653002900106653002600135653002300161100001400184700001300198700001400211700001200225700001300237700001200250245011700262856006600379300000800445490000600453520157900459022001402038       2018                            d10aNeglected tropical diseases (NTDs)10aLymphatic filariasis10aMass drug administration10aOverall coverage rate10aPatient Compliance1 aAlwala RR1 aBolla CR1 aDudala SR1 aRaju PY1 aMondal R1 aKumar R00aCoverage and compliance of mass drug administration for elimination of lymphatic filariasis in Khammam district.  uhttp://ijcmph.com/index.php/ijcmph/article/download/4013/2571  a1-50 v53 a<p><strong>Background:</strong> Lymphatic filariasis (LF) is an important public health and socio-economic problem in the world and it was identified as one of the six diseases, which could be targeted for elimination /eradication. Annual mass drug administration of DEC with selective vector control could result in the effective elimination of infection by interruption of transmission. The present study aimed to find the coverage and compliance of mass drug administration (MDA) of diethyl-carbamazine (DEC) for elimination of lymphatic filariasis (LF) in Khammam district in November 2009.</p>

<p><strong>Methods:</strong> Cross-sectional, population-based, house-to-house survey was conducted after the round of MDA with DEC. Multi-stage systematic sampling method was used and four clusters were selected with 30 houses in each. A pretested questionnaire was used to interview the study participants. The data collected was analyzed and coverage rate, compliance rate and effective coverage rate were calculated.</p>

<p><strong>Results:</strong> The coverage rate was 65.54% with variation across different areas. The compliance with drug ingestion was 71.14%. The effective coverage (46.63%) was much below the target (85%) which has to be targeted by intensive information, education and communication (IEC). Side effects of DEC were minimum, transient and drug-specific.</p>

<p><strong>Conclusions:</strong> The coverage, compliance, and effective coverage rates were found to be lower than the target, which need to be intensified by extensive IEC.</p>
  a2394-6032